Cutaneous melanoma · line 2 · Nivolumab + ipilimumab (melanoma, 1L metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-NIVO-IPI-MELANOMA`

ID	`IND-MELANOMA-2L-POST-BRAFI-IPI-NIVO`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-CHECKMATE-067-LARKIN-2019` `SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for BRAF V600+ metastatic melanoma where 1L was BRAFi+MEKi (visceral crisis / brain mets indication). Reuses REG-NIVO-IPI-MELANOMA (CheckMate-067 dosing schedule). Note: 2L-after-BRAFi cohorts in CheckMate-067 were small; outcome estimates extrapolate from 1L registration cohort.

Used By

Algorithms

ALGO-MELANOMA-METASTATIC-2L - ALGO-MELANOMA-METASTATIC-2L